Disease-specific autoantibodies in primary biliary cirrhosis

Clinica Chimica Acta

Volumn 412, Issue 7-8, 2011, Pages 502-512

  Bogdanos, Dimitrios P ^a   Komorowski, Lars ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Institute of Experimental Immunology   (Germany)

Author keywords

Autoantibody; Autoimmune liver diseases; ELISA; Indirect immunofluorescence; Serology; Test

Indexed keywords

ALKALINE PHOSPHATASE; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; CENTROMERE ANTIBODY; GAMMA GLUTAMYLTRANSFERASE; LIVER ANTIGEN; MITOCHONDRION ANTIBODY; SMOOTH MUSCLE ANTIBODY;

ANTIBODY DETECTION; ANTIBODY SCREENING; AUTOIMMUNE DISEASE; AUTOIMMUNITY; BILIARY TRACT FIBROSIS; CELL DESTRUCTION; CHOLESTASIS; COMPLEMENT FIXATION TEST; CYTOCHEMISTRY; DIAGNOSTIC VALUE; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; EPITHELIUM CELL; HUMAN; IMMUNOFLUORESCENCE; KIDNEY PARENCHYMA; LIVER BIOPSY; LIVER CELL NUCLEUS; LIVER FAILURE; LIVER PARENCHYMA; NONHUMAN; PREVALENCE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RODENT; STOMACH; WESTERN BLOTTING;

ANIMALS; AUTOANTIBODIES; HUMANS; LIVER CIRRHOSIS, BILIARY; PREVALENCE;

RODENTIA;

EID: 79551490697     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.12.019     Document Type: Review

References (150)

1. Kaplan M.M., Gershwin M.E. Primary biliary cirrhosis. N Engl J Med 2005, 353:1261-1273.
2. Hohenester S., Oude-Elferink R.P., Beuers U. Primary biliary cirrhosis. Semin Immunopathol 2009, 31:283-307.
3. Milkiewicz P. Liver transplantation in primary biliary cirrhosis. Clin Liver Dis 2008, 12:461-472.
4. Gershwin M.E., Selmi C., Worman H.J., et al. Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients. Hepatology 2005, 42:1194-1202.
5. Hudson M., Rojas-Villarraga A., Coral-Alvarado P., et al. Polyautoimmunity and familial autoimmunity in systemic sclerosis. J Autoimmun 2008, 31:156-159.
6. Kumagi T., Onji M. Presentation and diagnosis of primary biliary cirrhosis in the 21st century. Clin Liver Dis 2008, 12:243-259.
7. Talwalkar J.A., Keach J.C., Angulo P., Lindor K.D. Overlap of autoimmune hepatitis and primary biliary cirrhosis: an evaluation of a modified scoring system. Am J Gastroenterol 2002, 97:1191-1197.
8. Dienes H.P., Erberich H., Dries V., Schirmacher P., Lohse A. Autoimmune hepatitis and overlap syndromes. Clin Liver Dis 2002, 6:349-362. vi.
9. Rust C., Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 2008, 14:3368-3373.
10. Pusl T., Beuers U. Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol 2005, 28:147-157.
11. Invernizzi P., Pasini S., Selmi C., Gershwin M.E., Podda M. Female predominance and X chromosome defects in autoimmune diseases. J Autoimmun 2009, 33:12-16.
12. Selmi C., Gershwin M.E. The role of environmental factors in primary biliary cirrhosis. Trends Immunol 2009, 30:415-420.
13. Walden H.R., Kirby J.A., Yeaman S.J., Gray J., Jones D.E., Palmer J.M. Xenobiotic incorporation into pyruvate dehydrogenase complex can occur via the exogenous lipoylation pathway. Hepatology 2008, 48:1874-1884.
14. Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol 2010, 52:745-758.
15. Gershwin M.E., Mackay I.R. The causes of primary biliary cirrhosis: convenient and inconvenient truths. Hepatology 2008, 47:737-745.
16. Liu X., Invernizzi P., Lu Y., et al. Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet 2010, 42:658-660.
17. Burroughs A.K., Butler P., Sternberg M.J., Baum H. Molecular mimicry in liver disease. Nature 1992, 358:377-378.
18. Van de W.J., Turchany J., Leung P.S., et al. Molecular mimicry in primary biliary cirrhosis. Evidence for biliary epithelial expression of a molecule cross-reactive with pyruvate dehydrogenase complex-E2. J Clin Invest 1993, 91:2653-2664.
19. Baum H. Mitochondrial antigens, molecular mimicry and autoimmune disease. Biochim Biophys Acta 1995, 1271:111-121.
20. Shimoda S., Nakamura M., Shigematsu H., et al. Mimicry peptides of human PDC-E2 163-176 peptide, the immunodominant T-cell epitope of primary biliary cirrhosis. Hepatology 2000, 31:1212-1216.
21. Baum H., Bogdanos D.P., Vergani D. Antibodies to Clp protease in primary biliary cirrhosis: possible role of a mimicking T-cell epitope. J Hepatol 2001, 34:785-787.
22. Parikh-Patel A., Gold E.B., Worman H., Krivy K.E., Gershwin M.E. Risk factors for primary biliary cirrhosis in a cohort of patients from the United States. Hepatology 2001, 33:16-21.
23. Bogdanos D.P., Baum H., Sharma U.C., et al. Antibodies against homologous microbial caseinolytic proteases P characterise primary biliary cirrhosis. J Hepatol 2002, 36:14-21.
24. Selmi C., Balkwill D.L., Invernizzi P., et al. Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. Hepatology 2003, 38:1250-1257.
25. Bogdanos D.P., Baum H., Grasso A., et al. Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. J Hepatol 2004, 40:31-39.
26. Bogdanos D.P., Pares A., Baum H., et al. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun 2004, 22:353-362.
27. Rieger R., Leung P.S., Jeddeloh M.R., et al. Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun 2006, 27:7-16.
28. Mason A.L., Zhang G. Linking human beta retrovirus infection with primary biliary cirrhosis. Gastroentérol Clin Biol 2010, 34:359-366.
29. Prince M.I., James O.F. The epidemiology of primary biliary cirrhosis. Clin Liver Dis 2003, 7:795-819.
30. Kaplan M.M. Primary biliary cirrhosis. N Engl J Med 1987, 316:521-528.
31. Lindor K.D., Gershwin M.E., Poupon R., Kaplan M., Bergasa N.V., Heathcote E.J. Primary biliary cirrhosis. Hepatology 2009, 50:291-308.
32. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237-267.
33. Mackay I.R. Primary biliary cirrhosis showing a high titer of autoantibody; report of a case. N Engl J Med 1958, 258:185-188.
34. Ahrens E.H., Payne M.A., Kunkel H.G., Eisenmenger W.J., Blondheim S.H. Primary biliary cirrhosis. Medicine 1950, 29:299-364. (Baltimore).
35. Addison T., Gull W. On a certain affection of the skin, vitiligoidea-a. plana, b. tuberosa. Guys Hosp Rep 1851, 7:265-276.
36. Ashersons G.L., Dumonde D.C. Characterization of auto-antibodies produced in the rabbit by the injection of rat liver. Br J Exp Pathol 1962, 43:12-20.
37. Walker J., Doniach D., Roitt I.M., Sherlock S. Serological tests in diagnosis of primary biliary cirrhosis. Lancet 1965, 1:827-831.
38. Berg P.A., Doniach D., Roitt I.M. Mitochondrial antibodies in primary biliary cirrhosis. I. Localization of the antigen to mitochondrial membranes. J Exp Med 1967, 126:277-290.
39. Berg P.A., Muscatello U., Horne R.W., Roitt I.M., Doniach D. Mitochondrial antibodies in primary biliary cirrhosis. II. The complement fixing antigen as a component of mitochondrial inner membranes. Br J Exp Pathol 1969, 50:200-208.
40. Berg P.A., Roitt I.M., Doniach D., Cooper H.M. Mitochondrial antibodies in primary biliary cirrhosis. IV. Significance of membrane structure for the complement-fixing antigen. Immunology 1969, 17:281-293.
41. Berg P.A., Roitt I.M., Doniach D., Horne R.W. Mitochondrial antibodies in primary biliary cirrhosis. 3. Characterization of the inner-membrane complement fixing antigen. Clin Exp Immunol 1969, 4:511-525.
42. Wright D.J., Doniach D., Lessof M.H., Turk J.L., Grimble A.S., Catterall R.D. New antibody in early syphilis. Lancet 1970, 1:740-743.
43. Berg P.A., Klein R. Antimitochondrial antibodies in primary biliary cirrhosis and other disorders: definition and clinical relevance. Dig Dis 1992, 10:85-101.
44. Berg C.P., Stein G.M., Klein R., et al. Demonstration of PDC-E1 subunits as major antigens in the complement-fixing fraction M4 and re-evaluation of PDC-E1-specific antibodies in PBC patients. Liver Int 2006, 26:846-855.
45. Feuchtinger M., Christ S., Preuss B., et al. Detection of novel non-M2-related antimitochondrial antibodies in patients with anti-M2 negative primary biliary cirrhosis. Gut 2009, 58:983-989.
46. Palmer J.M., Yeaman S.J., Bassendine M.F., James O.F. M4 and M9 autoantigens in primary biliary cirrhosis-a negative study. J Hepatol 1993, 18:251-254.
47. Davis P.A., Leung P., Manns M., et al. M4 and M9 antibodies in the overlap syndrome of primary biliary cirrhosis and chronic active hepatitis: epitopes or epiphenomena?. Hepatology 1992, 16:1128-1136.
48. Joshi S., Cauch-Dudek K., Heathcote E.J., Lindor K., Jorgensen R., Klein R. Antimitochondrial antibody profiles: are they valid prognostic indicators in primary biliary cirrhosis?. Am J Gastroenterol 2002, 97:999-1002.
49. Invernizzi P., Selmi C., Ranftler C., Podda M., Wesierska-Gadek J. Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 2005, 25:298-310.
50. Granito A., Yang W.H., Muratori L., et al. PML nuclear body component Sp140 is a novel autoantigen in primary biliary cirrhosis. Am J Gastroenterol 2010, 105:125-131.
51. Sternsdorf T., Guldner H.H., Szostecki C., Grotzinger T., Will H. Two nuclear dot-associated proteins, PML and Sp100, are often co-autoimmunogenic in patients with primary biliary cirrhosis. Scand J Immunol 1995, 42:257-268.
52. Courvalin J.C., Lassoued K., Bartnik E., Blobel G., Wozniak R.W. The 210-kD nuclear envelope polypeptide recognized by human autoantibodies in primary biliary cirrhosis is the major glycoprotein of the nuclear pore. J Clin Invest 1990, 86:279-285.
53. Wesierska-Gadek J., Hohenuer H., Hitchman E., Penner E. Autoantibodies against nucleoporin p62 constitute a novel marker of primary biliary cirrhosis. Gastroenterology 1996, 110:840-847.
54. Rigopoulou E.I., Davies E.T., Pares A., et al. Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut 2005, 54:528-532.
55. Vergani D., Bogdanos D.P. Positive markers in AMA-negative PBC. Am J Gastroenterol 2003, 98:241-243.
56. Nakamura M., Kondo H., Mori T., et al. Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 2007, 45:118-127.
57. Yang W.H., Yu J.H., Nakajima A., Neuberg D., Lindor K., Bloch D.B. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure?. Clin Gastroenterol Hepatol 2004, 2:1116-1122.
58. Marasini B., Gagetta M., Rossi V., Ferrari P. Rheumatic disorders and primary biliary cirrhosis: an appraisal of 170 Italian patients. Ann Rheum Dis 2001, 60:1046-1049.
59. Wesierska-Gadek J., Penner E., Battezzati P.M., et al. Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 2006, 43:1135-1144.
60. Muratori P., Muratori L., Ferrari R., et al. Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 2003, 98:431-437.
61. Invernizzi P., Podda M., Battezzati P.M., et al. Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 2001, 34:366-372.
62. Itoh S., Ichida T., Yoshida T., et al. Autoantibodies against a 210kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 1998, 13:257-265.
63. Miyachi K., Hankins R.W., Matsushima H., et al. Profile and clinical significance of anti-nuclear envelope antibodies found in patients with primary biliary cirrhosis: a multicenter study. J Autoimmun 2003, 20:247-254.
64. Lassoued K., Guilly M.N., Andre C., et al. Autoantibodies to 200 kD polypeptide(s) of the nuclear envelope: a new serologic marker of primary biliary cirrhosis. Clin Exp Immunol 1988, 74:283-288.
65. Bogdanos D.P., Liaskos C., Pares A., et al. Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology 2007, 45:1583-1584.
66. Parveen S., Morshed S.A., Nishioka M. High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. J Gastroenterol Hepatol 1995, 10:438-445.
67. Rigamonti C., Shand L.M., Feudjo M., et al. Clinical features and prognosis of primary biliary cirrhosis associated with systemic sclerosis. Gut 2006, 55:388-394.
68. Bogdanos D.P., Invernizzi P., Mackay I.R., Vergani D. Autoimmune liver serology: current diagnostic and clinical challenges. World J Gastroenterol 2008, 14:3374-3387.
69. Czaja A.J., Homburger H.A. Autoantibodies in liver disease. Gastroenterology 2001, 120:239-249.
70. Alvarez F., Berg P.A., Bianchi F.B., et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999, 31:929-938.
71. Hennes E.M., Zeniya M., Czaja A.J., et al. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008, 48:169-176.
72. Manns M.P., Czaja A.J., Gorham J.D., et al. Diagnosis and management of autoimmune hepatitis. Hepatology 2010, 51:2193-2213.
73. Villalta D., Bizzaro N., Da Re M., Tozzoli R., Komorowski L., Tonutti E. Diagnostic accuracy of four different immunological methods for the detection of anti-F-actin autoantibodies in type 1 autoimmune hepatitis and other liver-related disorders. Autoimmunity 2008, 41:105-110.
74. Manns M.P., Griffin K.J., Sullivan K.F., Johnson E.F. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991, 88:1370-1378.
75. Lapierre P., Hajoui O., Homberg J.C., Alvarez F. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999, 116:643-649.
76. Muratori L., Sztul E., Muratori P., et al. Distinct epitopes on formiminotransferase cyclodeaminase induce autoimmune liver cytosol antibody type 1. Hepatology 2001, 34:494-501.
77. Wies I., Brunner S., Henninger J., et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000, 355:1510-1515.
78. Teegen B., Niemann S., Probst C., Schlumberger W., Stöcker W., Komorowski L. DNA-bound lactoferrin is the major target for antineutrophil perinuclear cytoplasmic antibodies in ulcerative colitis. Ann NY Acad Sci 2009, 1173:161-165.
79. Wandinger K.P., Probst C., Komorowski L., et al. Novel recombinant antigenic targets for the determination of (auto)antibodies in autoimmune dermatoses, neurological disorders and gastrointestinal diseases. From Pathogenesis to Therapy of Autoimmune Diseases. Report on the 9th Dresden Symposium on Autoantibodies 2009, 179-190. Pabst Science Publishers, Dresden. 6 ed. K. Conrad, E.K. Chan, M.J. Fritzler, R.L. Humbel, P. van Landenberg, Y. Shoenfeld (Eds.).
80. Terjung B., Soehne J., Lechtenberg B., et al. p-ANCA in autoimmune liver disorders recognize human beta-tubulin isotype 5 and cross-react with microbial protein FtsZ. Gut 2010, 56:410-418.
81. Chazouilleres O., Wendum D., Serfaty L., Montembault S., Rosmorduc O., Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998, 28:296-301.
82. Czaja A.J., Manns M.P. Advances in the diagnosis, pathogenesis, and management of autoimmune hepatitis. Gastroenterology 2010, 139:58-72.
83. Bassendine M.F., Jones D.E., Yeaman S.J. Biochemistry and autoimmune response to the 2-oxoacid dehydrogenase complexes in primary biliary cirrhosis. Semin Liver Dis 1997, 17:49-60.
84. Lindenborn-Fotinos J., Baum H., Berg P.A. Mitochondrial antibodies in primary biliary cirrhosis: species and nonspecies specific determinants of M2 antigen. Hepatology 1985, 5:763-769.
85. Gershwin M.E., Mackay I.R., Sturgess A., Coppel R.L. Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. J Immunol 1987, 138:3525-3531.
86. Yeaman S.J., Fussey S.P., Danner D.J., James O.F., Mutimer D.J., Bassendine M.F. Primary biliary cirrhosis: identification of two major M2 mitochondrial autoantigens. Lancet 1988, 1:1067-1070.
87. Fussey S.P., Bassendine M.F., Fittes D., Turner I.B., James O.F., Yeaman S.J. The E1 alpha and beta subunits of the pyruvate dehydrogenase complex are M2'd' and M2'e' autoantigens in primary biliary cirrhosis. Clin Sci 1989, 77:365-368. (Lond).
88. Van de W.J., Surh C.D., Leung P.S., et al. Molecular definitions, autoepitopes, and enzymatic activities of the mitochondrial autoantigens of primary biliary cirrhosis. Semin Liver Dis 1989, 9:132-137.
89. Bogdanos D.P., Baum H., Vergani D. Antimitochondrial and other autoantibodies. Clin Liver Dis 2003, 7:759-777.
90. Leung P.S., Coppel R.L., Ansari A., Munoz S., Gershwin M.E. Antimitochondrial antibodies in primary biliary cirrhosis. Semin Liver Dis 1997, 17:61-69.
91. Mori T., Ono K., Hakozaki M., Kasukawa R., Kochi H. Autoantibodies of sera from patients with primary biliary cirrhosis recognize the alpha subunit of the decarboxylase component of human branched-chain 2-oxo acid dehydrogenase complex. J Hepatol 2001, 34:799-804.
92. Muratori L., Granito A., Muratori P., Pappas G., Bianchi F.B. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis 2008, 12:261-276.
93. Rigopoulou E.I., Bogdanos D.P., Liaskos C., et al. Anti-mitochondrial antibody immunofluorescent titres correlate with the number and intensity of immunoblot-detected mitochondrial bands in patients with primary biliary cirrhosis. Clin Chim Acta 2007, 380:118-121.
94. Van de W.J., Cooper A., Surh C.D., et al. Detection of autoantibodies to recombinant mitochondrial proteins in patients with primary biliary cirrhosis. N Engl J Med 1989, 320:1377-1380.
95. Muratori L., Muratori P., Granito A., et al. The Western immunoblotting pattern of anti-mitochondrial antibodies is independent of the clinical expression of primary biliary cirrhosis. Dig Liver Dis 2005, 37:108-112.
96. Palmer J.M., Jones D.E., Quinn J., McHugh A., Yeaman S.J. Characterization of the autoantibody responses to recombinant E3 binding protein (protein X) of pyruvate dehydrogenase in primary biliary cirrhosis. Hepatology 1999, 30:21-26.
97. Dubel L., Tanaka A., Leung P.S., et al. Autoepitope mapping and reactivity of autoantibodies to the dihydrolipoamide dehydrogenase-binding protein (E3BP) and the glycine cleavage proteins in primary biliary cirrhosis. Hepatology 1999, 29:1013-1018.
98. Bogdanos D.P., Vergani D. Origin of cross-reactive autoimmunity in primary biliary cirrhosis. Liver Int 2006, 26:633-635.
99. Van de W.J., Fregeau D., Davis P., et al. Autoantibodies of primary biliary cirrhosis recognize dihydrolipoamide acetyltransferase and inhibit enzyme function. J Immunol 1988, 141:2321-2324.
100. Rowley M.J., McNeilage L.J., Armstrong J.M., Mackay I.R. Inhibitory autoantibody to a conformational epitope of the pyruvate dehydrogenase complex, the major autoantigen in primary biliary cirrhosis. Clin Immunol Immunopathol 1991, 60:356-370.
101. Dähnrich C., Pares A., Caballeria L., et al. New ELISA for detecting primary biliary cirrhosis-specific antimitochondrial antibodies. Clin Chem 2009, 55:978-985.
102. Oertelt S., Rieger R., Selmi C., et al. A sensitive bead assay for antimitochondrial antibodies: chipping away at AMA-negative primary biliary cirrhosis. Hepatology 2007, 45:659-665.
103. Invernizzi P., Lleo A., Podda M. Interpreting serological tests in diagnosing autoimmune liver diseases. Semin Liver Dis 2007, 27:161-172.
104. Lleo A., Invernizzi P., Gao B., Podda M., Gershwin M.E. Definition of human autoimmunity-autoantibodies versus autoimmune disease. Autoimmun Rev 2010, 9:A259-A266.
105. Invernizzi P., Crosignani A., Battezzati P.M., et al. Comparison of the clinical features and clinical course of antimitochondrial antibody-positive and -negative primary biliary cirrhosis. Hepatology 1997, 25:1090-1095.
106. Masuda J., Omagari K., Ohba K., et al. Correlation between histopathological findings of the liver and IgA class antibodies to 2-oxo-acid dehydrogenase complex in primary biliary cirrhosis. Dig Dis Sci 2003, 48:932-938.
107. Van Norstrand M.D., Malinchoc M., Lindor K.D., et al. Quantitative measurement of autoantibodies to recombinant mitochondrial antigens in patients with primary biliary cirrhosis: relationship of levels of autoantibodies to disease progression. Hepatology 1997, 25:6-11.
108. Rigopoulou E.I., Davies E.T., Bogdanos D.P., et al. Antimitochondrial antibodies of immunoglobulin G3 subclass are associated with a more severe disease course in primary biliary cirrhosis. Liver Int 2007, 27:1226-1231.
109. Miyakawa H., Kawaguchi N., Kikuchi K., et al. False positive reaction in ELISA for IgM class anti-M2 antibody and its prevention. Hepatol Res 2001, 20:279-287.
110. Mutimer D.J., Fussey S.P., Yeaman S.J., Kelly P.J., James O.F., Bassendine M.F. Frequency of IgG and IgM autoantibodies to four specific M2 mitochondrial autoantigens in primary biliary cirrhosis. Hepatology 1989, 10:403-407.
111. Surh C.D., Cooper A.E., Coppel R.L., et al. The predominance of IgG3 and IgM isotype antimitochondrial autoantibodies against recombinant fused mitochondrial polypeptide in patients with primary biliary cirrhosis. Hepatology 1988, 8:290-295.
112. Mendel-Hartvig I., Frostell A., Totterman T.H. Primary biliary cirrhosis: antigenic specificity of IgM-type mitochondrial antibodies analyzed by immunoblotting and ELISA. Int Arch Allergy Appl Immunol 1987, 83:265-270.
113. Omagari K., Kadokawa Y., Nakamura M., et al. IgA class antibodies to 2-oxo-acid dehydrogenase complex are not predictive markers of histopathological progression in primary biliary cirrhosis. Autoimmunity 2006, 39:107-112.
114. Tanaka A., Nezu S., Uegaki S., et al. The clinical significance of IgA antimitochondrial antibodies in sera and saliva in primary biliary cirrhosis. Ann NY Acad Sci 2007, 1107:259-270.
115. Nakajima M., Shimizu H., Miyazaki A., Watanabe S., Kitami N., Sato N. Detection of IgA, IgM, and IgG subclasses of anti-M2 antibody by immunoblotting in autoimmune cholangitis: is autoimmune cholangitis an early stage of primary biliary cirrhosis?. J Gastroenterol 1999, 34:607-612.
116. Miyakawa H., Tanaka A., Kikuchi K., et al. Detection of antimitochondrial autoantibodies in immunofluorescent AMA-negative patients with primary biliary cirrhosis using recombinant autoantigens. Hepatology 2001, 34:243-248.
117. Prince M., Chetwynd A., Newman W., Metcalf J.V., James O.F. Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28years. Gastroenterology 2002, 123:1044-1051.
118. Invernizzi P., Selmi C., Gershwin M.E. Update on primary biliary cirrhosis. Dig Liver Dis 2010, 42:401-408.
119. Metcalf J.V., Mitchison H.C., Palmer J.M., Jones D.E., Bassendine M.F., James O.F. Natural history of early primary biliary cirrhosis. Lancet 1996, 348:1399-1402.
120. Mitchison H.C., Bassendine M.F., Hendrick A., et al. Positive antimitochondrial antibody but normal alkaline phosphatase: is this primary biliary cirrhosis?. Hepatology 1986, 6:1279-1284.
121. Hannam S., Bogdanos D.P., Davies E.T., et al. Neonatal liver disease associated with placental transfer of anti-mitochondrial antibodies. Autoimmunity 2002, 35:545-550.
122. Jones D.E. Pathogenesis of primary biliary cirrhosis. Clin Liver Dis 2008, 12:305-321.
123. Kumagi T., Heathcote E.J. Primary biliary cirrhosis. Orphanet J Rare Dis 2008, 3:1.
124. Mattalia A., Quaranta S., Leung P.S., et al. Characterization of antimitochondrial antibodies in healthy adults. Hepatology 1998, 27:656-661.
125. Selmi, C., Pasini, S., Invernizzi, P. et al. The prevalence of serum anti-mitochondrial antibody using recombinant autoantigens demonstrates unexpectedly high rates and male representation in the general population. 44th Annual Meeting of the European Association for the Study of the Liver, Copenhagen. 2009.
126. Lazaridis K.N., Juran B.D., Boe G.M., et al. Increased prevalence of antimitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis. Hepatology 2007, 46:785-792.
127. Neuberger J., Thomson R. PBC and AMA-what is the connection?. Hepatology 1999, 29:271-276.
128. Lee Y.M., Kaplan M.M. The natural history of PBC: has it changed?. Semin Liver Dis 2005, 25:321-326.
129. Kim W.R., Lindor K.D., Locke G.R., et al. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000, 119:1631-1636.
130. Nouri-Aria K.T., Hegarty J.E., Neuberger J., Eddleston A.L., Williams R. In vitro studies on the mechanism of increased serum IgM levels in primary biliary cirrhosis. Clin Exp Immunol 1985, 61:297-304.
131. Leung P.S., Rossaro L., Davis P.A., et al. Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology 2007, 46:1436-1442.
132. Bernal W., Meda F., Ma Y., Bogdanos D.P., Vergani D. Disease-specific autoantibodies in patients with acute liver failure: the King's College London Experience. Hepatology 2008, 47:1096-1097.
133. Muratori P., Muratori L., Gershwin M.E., et al. 'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both?. Clin Exp Immunol 2004, 135:154-158.
134. Selmi C., Meda F., Kasangian A., et al. Experimental evidence on the immunopathogenesis of primary biliary cirrhosis. Cell Mol Immunol 2010, 7:1-10.
135. Doniach D., Lindqvist H.L., Berg P.A. Non-organ-specific cytoplasmic antibodies detected by immunofluorescence. Int Arch Allergy Appl Immunol 1971, 41:501-513.
136. Goudie R.B., MacSween R.N., Goldberg D.M. Serological and histological diagnosis of primary biliary cirrhosis. J Clin Pathol 1966, 19:527-538.
137. Kaplan M.M., Gandolfo J.V., Quaroni E.G. An enzyme-linked immunosorbent assay (ELISA) for detecting antimitochondrial antibody. Hepatology 1984, 4:727-730.
138. Gabeta S., Norman G.L., Liaskos C., et al. Diagnostic relevance and clinical significance of the new enhanced performance M2 (MIT3) ELISA for the detection of IgA and IgG antimitochondrial antibodies in primary biliary cirrhosis. J Clin Immunol 2007, 27:378-387.
139. Kadokawa Y., Omagari K., Hazama H., et al. Evaluation of newly developed ELISA using "MESACUP-2 test mitochondrial M2" kit for the diagnosis of primary biliary cirrhosis. Clin Biochem 2003, 36:203-210.
140. Moteki S., Leung P.S., Coppel R.L., et al. Use of a designer triple expression hybrid clone for three different lipoyl domain for the detection of antimitochondrial autoantibodies. Hepatology 1996, 24:97-103.
141. Bargou I., Mankai A., Jamaa A., et al. Detection of M2 antimitochondrial antibodies by dot blot assay is more specific than by enzyme linked immunosorbent assay. Pathol Biol 2008, 56:10-14. (Paris).
142. Janssen A., Komorowski L., Bogdanos D.P., et al. Parrallel detection of PBC-associated autoantibodies using a new line immunoassay 2008, International Workshop on Autoantibodies and Autoimmunity, Guadalajara.
143. Meyer W., Scheper T., Janssen N., et al. A comprehensive line immunoassay for the detection of autoantibodies in primary biliary cirrhosis. From Etiopathogenesis to the Prediction of Autoimmune Diseases: Relevance of Autoantibodies. Report on the 8th Dresden Symposium on Autoantibodies 2007, 323-325. Pabst Science Publishers, Dresden. 5 ed. K. Conrad, E.K. Chan, M.J. Fritzler, U. Sack, Y. Shoenfeld, A. Wiik (Eds.).
144. Stanley C.J., Perham R.N. Purification of 2-oxo acid dehydrogenase multienzyme complexes from ox heart by a new method. Biochem J 1980, 191:147-154.
145. Miyakawa H., Kikuchi K., Jong-Hon K., et al. High sensitivity of a novel ELISA for anti-M2 in primary biliary cirrhosis. J Autoimmun 2010, 35(4):436-442.
146. Liu H., Norman G.L., Shums Z., et al. PBC Screen: An IgG/IgA dual isotype ELISA detecting multiple mitochondrial and nuclear autoantibodies specific for primary biliary cirrhosis. J Autoimmun 2010.
147. Janssen A., Meyer W., Scheper T., et al. Analysis of specific autoantibody profiles in primary biliary cirrhosis. J Hepatol 2008, 48:S326-S327.
148. Teoh K.L., Rowley M.J., Mackay I.R. An automated microassay for enzyme inhibitory effects of M2 antibodies in primary biliary cirrhosis. Liver 1991, 11:287-291.
149. Bogdanos D.P., Mieli-Vergani G., Vergani D. Autoantibodies and their antigens in autoimmune hepatitis. Semin Liver Dis 2009, 29:241-253.
150. Rondeel J.M., van Gelder W., van der Leeden H., Dinkelaar R.B. Different strategies in the laboratory diagnosis of autoimmune disease: immunofluorescence, enzyme-linked immunosorbent assay or both?. Ann Clin Biochem 1999, 36(Pt 2):189-195.